Cargando…

Efficacy of a nootropic spearmint extract on reactive agility: a randomized, double-blind, placebo-controlled, parallel trial

BACKGROUND: Proprietary spearmint extract (PSE) containing a minimum 14.5% rosmarinic acid and 24% total phenolic content, has evinced positive effects on cognition in individuals aged 50–70 with memory impairment after chronic supplementation. To address the growing interest in connecting mental an...

Descripción completa

Detalles Bibliográficos
Autores principales: Falcone, Paul H., Tribby, Aaron C., Vogel, Roxanne M., Joy, Jordan M., Moon, Jordan R., Slayton, Chantelle A., Henigman, Micah M., Lasrado, Joanne A., Lewis, Brandon J., Fonseca, Brenda A., Nieman, Kristin M., Herrlinger, Kelli A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6291964/
https://www.ncbi.nlm.nih.gov/pubmed/30541572
http://dx.doi.org/10.1186/s12970-018-0264-5
_version_ 1783380316529885184
author Falcone, Paul H.
Tribby, Aaron C.
Vogel, Roxanne M.
Joy, Jordan M.
Moon, Jordan R.
Slayton, Chantelle A.
Henigman, Micah M.
Lasrado, Joanne A.
Lewis, Brandon J.
Fonseca, Brenda A.
Nieman, Kristin M.
Herrlinger, Kelli A.
author_facet Falcone, Paul H.
Tribby, Aaron C.
Vogel, Roxanne M.
Joy, Jordan M.
Moon, Jordan R.
Slayton, Chantelle A.
Henigman, Micah M.
Lasrado, Joanne A.
Lewis, Brandon J.
Fonseca, Brenda A.
Nieman, Kristin M.
Herrlinger, Kelli A.
author_sort Falcone, Paul H.
collection PubMed
description BACKGROUND: Proprietary spearmint extract (PSE) containing a minimum 14.5% rosmarinic acid and 24% total phenolic content, has evinced positive effects on cognition in individuals aged 50–70 with memory impairment after chronic supplementation. To address the growing interest in connecting mental and physical performance, the present study examined whether the nootropic effects of PSE translate into changes in reactive agility following daily supplementation with PSE. METHODS: Utilizing a randomized, double-blind, placebo-controlled, parallel design, healthy, recreationally-active men and women (n = 142) received 900 mg of PSE or placebo (PLA) daily for 90 days. Reactive agility, our primary outcome, was determined by measuring the number of hits and average reaction time (ART) on a Makoto Arena II, a 360(0) audio-visual device that measures stationary, lateral, and multi-directional active choice reaction performance. Safety was evaluated using complete blood count, comprehensive metabolic panel, and blood lipids. Measurements were evaluated on days 7, 30, and 90 of supplementation. RESULTS: An overall treatment effect (p = 0.019) was evident for increased hits with PSE on the stationary test with footplates, with between group differences at Day 30 (PSE vs. PLA: 28.96 ± 2.08 vs. 28.09 ± 1.92 hits; p = 0.040) and Day 90 (PSE vs. PLA: 28.42 ± 2.54 vs. 27.02 ± 3.55 hits; p = 0.002). On the same task, ART improved (treatment effect, p = 0.036) with PSE at Day 7 (PSE vs. PLA: 0.5896 ± 0.060 vs. 0.6141 ± 0.073 s; p = 0.049) and Day 30 (PSE vs. PLA: 0.5811 ± 0.068 vs. 0.6033 ± 0.055 s; p = 0.049). PSE also significantly increased hits (treatment effect, p = 0.020) at Day 30 (PSE vs. PLA: 19.25 ± 1.84 vs. 18.45 ± 1.48 hits; p = 0.007) and Day 90 (PSE vs. PLA: 19.39 ± 1.90 vs. 18.66 ± 1.64 hits; p = 0.026) for the multi-directional test with footplates. Significant differences were not observed in the remaining Makoto tests. PSE was well tolerated as evidenced by no effects observed in the blood safety panels. CONCLUSIONS: The findings of the current study demonstrate that consumption of 900 mg of PSE improved specific measures of reactive agility in a young, active population. TRIAL REGISTRATION: clinicaltrials.gov, NCT02518165. Registered August 7, 2015 – retrospectively registered. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s12970-018-0264-5) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-6291964
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-62919642018-12-17 Efficacy of a nootropic spearmint extract on reactive agility: a randomized, double-blind, placebo-controlled, parallel trial Falcone, Paul H. Tribby, Aaron C. Vogel, Roxanne M. Joy, Jordan M. Moon, Jordan R. Slayton, Chantelle A. Henigman, Micah M. Lasrado, Joanne A. Lewis, Brandon J. Fonseca, Brenda A. Nieman, Kristin M. Herrlinger, Kelli A. J Int Soc Sports Nutr Research Article BACKGROUND: Proprietary spearmint extract (PSE) containing a minimum 14.5% rosmarinic acid and 24% total phenolic content, has evinced positive effects on cognition in individuals aged 50–70 with memory impairment after chronic supplementation. To address the growing interest in connecting mental and physical performance, the present study examined whether the nootropic effects of PSE translate into changes in reactive agility following daily supplementation with PSE. METHODS: Utilizing a randomized, double-blind, placebo-controlled, parallel design, healthy, recreationally-active men and women (n = 142) received 900 mg of PSE or placebo (PLA) daily for 90 days. Reactive agility, our primary outcome, was determined by measuring the number of hits and average reaction time (ART) on a Makoto Arena II, a 360(0) audio-visual device that measures stationary, lateral, and multi-directional active choice reaction performance. Safety was evaluated using complete blood count, comprehensive metabolic panel, and blood lipids. Measurements were evaluated on days 7, 30, and 90 of supplementation. RESULTS: An overall treatment effect (p = 0.019) was evident for increased hits with PSE on the stationary test with footplates, with between group differences at Day 30 (PSE vs. PLA: 28.96 ± 2.08 vs. 28.09 ± 1.92 hits; p = 0.040) and Day 90 (PSE vs. PLA: 28.42 ± 2.54 vs. 27.02 ± 3.55 hits; p = 0.002). On the same task, ART improved (treatment effect, p = 0.036) with PSE at Day 7 (PSE vs. PLA: 0.5896 ± 0.060 vs. 0.6141 ± 0.073 s; p = 0.049) and Day 30 (PSE vs. PLA: 0.5811 ± 0.068 vs. 0.6033 ± 0.055 s; p = 0.049). PSE also significantly increased hits (treatment effect, p = 0.020) at Day 30 (PSE vs. PLA: 19.25 ± 1.84 vs. 18.45 ± 1.48 hits; p = 0.007) and Day 90 (PSE vs. PLA: 19.39 ± 1.90 vs. 18.66 ± 1.64 hits; p = 0.026) for the multi-directional test with footplates. Significant differences were not observed in the remaining Makoto tests. PSE was well tolerated as evidenced by no effects observed in the blood safety panels. CONCLUSIONS: The findings of the current study demonstrate that consumption of 900 mg of PSE improved specific measures of reactive agility in a young, active population. TRIAL REGISTRATION: clinicaltrials.gov, NCT02518165. Registered August 7, 2015 – retrospectively registered. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s12970-018-0264-5) contains supplementary material, which is available to authorized users. BioMed Central 2018-12-12 /pmc/articles/PMC6291964/ /pubmed/30541572 http://dx.doi.org/10.1186/s12970-018-0264-5 Text en © The Author(s). 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Falcone, Paul H.
Tribby, Aaron C.
Vogel, Roxanne M.
Joy, Jordan M.
Moon, Jordan R.
Slayton, Chantelle A.
Henigman, Micah M.
Lasrado, Joanne A.
Lewis, Brandon J.
Fonseca, Brenda A.
Nieman, Kristin M.
Herrlinger, Kelli A.
Efficacy of a nootropic spearmint extract on reactive agility: a randomized, double-blind, placebo-controlled, parallel trial
title Efficacy of a nootropic spearmint extract on reactive agility: a randomized, double-blind, placebo-controlled, parallel trial
title_full Efficacy of a nootropic spearmint extract on reactive agility: a randomized, double-blind, placebo-controlled, parallel trial
title_fullStr Efficacy of a nootropic spearmint extract on reactive agility: a randomized, double-blind, placebo-controlled, parallel trial
title_full_unstemmed Efficacy of a nootropic spearmint extract on reactive agility: a randomized, double-blind, placebo-controlled, parallel trial
title_short Efficacy of a nootropic spearmint extract on reactive agility: a randomized, double-blind, placebo-controlled, parallel trial
title_sort efficacy of a nootropic spearmint extract on reactive agility: a randomized, double-blind, placebo-controlled, parallel trial
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6291964/
https://www.ncbi.nlm.nih.gov/pubmed/30541572
http://dx.doi.org/10.1186/s12970-018-0264-5
work_keys_str_mv AT falconepaulh efficacyofanootropicspearmintextractonreactiveagilityarandomizeddoubleblindplacebocontrolledparalleltrial
AT tribbyaaronc efficacyofanootropicspearmintextractonreactiveagilityarandomizeddoubleblindplacebocontrolledparalleltrial
AT vogelroxannem efficacyofanootropicspearmintextractonreactiveagilityarandomizeddoubleblindplacebocontrolledparalleltrial
AT joyjordanm efficacyofanootropicspearmintextractonreactiveagilityarandomizeddoubleblindplacebocontrolledparalleltrial
AT moonjordanr efficacyofanootropicspearmintextractonreactiveagilityarandomizeddoubleblindplacebocontrolledparalleltrial
AT slaytonchantellea efficacyofanootropicspearmintextractonreactiveagilityarandomizeddoubleblindplacebocontrolledparalleltrial
AT henigmanmicahm efficacyofanootropicspearmintextractonreactiveagilityarandomizeddoubleblindplacebocontrolledparalleltrial
AT lasradojoannea efficacyofanootropicspearmintextractonreactiveagilityarandomizeddoubleblindplacebocontrolledparalleltrial
AT lewisbrandonj efficacyofanootropicspearmintextractonreactiveagilityarandomizeddoubleblindplacebocontrolledparalleltrial
AT fonsecabrendaa efficacyofanootropicspearmintextractonreactiveagilityarandomizeddoubleblindplacebocontrolledparalleltrial
AT niemankristinm efficacyofanootropicspearmintextractonreactiveagilityarandomizeddoubleblindplacebocontrolledparalleltrial
AT herrlingerkellia efficacyofanootropicspearmintextractonreactiveagilityarandomizeddoubleblindplacebocontrolledparalleltrial